Research programme: BUB1 kinase inhibitors - Bayer PharmaAlternative Names: BAY-320; BAY-524
Latest Information Update: 03 May 2016
At a glance
- Originator Bayer
- Class Small molecules
- Mechanism of Action Bub1 spindle checkpoint protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Apr 2016 Preclinical trials in Cancer in Germany (unspecified route) prior to April 2016